title: Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.
abstract: Neutrophil elastase and cathepsin G are abundant intracellular neutrophil proteinases that have an important role in destroying ingested particles. However, when neutrophils degranulate, these proteinases are released and can cause irreparable damage by degrading host connective tissue proteins. Despite abundant endogenous inhibitors, these proteinases are protected from inhibition because of their ability to bind to anionic surfaces. Plasminogen activator inhibitor type-1 (PAI-1), which is not an inhibitor of these proteinases, possesses properties that could make it an effective inhibitor of neutrophil proteinases if its specificity could be redirected. PAI-1 efficiently inhibits surface-sequestered proteinases, and it efficiently mediates rapid cellular clearance of PAI-1-proteinase complexes. Therefore, we examined whether PAI-1 could be engineered to inhibit and clear neutrophil elastase and cathepsin G. By introducing specific mutations in the reactive center loop of wild-type PAI-1, we generated PAI-1 mutants that are effective inhibitors of both proteinases. Kinetic analysis shows that the inhibition of neutrophil proteinases by these PAI-1 mutants is not affected by the sequestration of neutrophil elastase and cathepsin G onto surfaces. In addition, complexes of these proteinases and PAI-1 mutants are endocytosed and degraded by lung epithelial cells more efficiently than either the neutrophil proteinases alone or in complex with their physiological inhibitors, alpha1-proteinase inhibitor and alpha1-antichymotrypsin. Finally, the PAI-1 mutants were more effective in reducing the neutrophil elastase and cathepsin G activities in an in vivo model of lung inflammation than were their physiological inhibitors.
authors.affiliation: Department of Vascular Biology, J. H. Holland Laboratory, Rockville, Maryland 20855, USA. StefansS@usa.redcross.org
authors.forename: Steingrimur
authors.initials: S
authors.lastname: Stefansson
authors.forename: Manuel
authors.initials: M
authors.lastname: Yepes
authors.forename: Natalia
authors.initials: N
authors.lastname: Gorlatova
authors.forename: Duane E
authors.initials: DE
authors.lastname: Day
authors.forename: Elisabeth G
authors.initials: EG
authors.lastname: Moore
authors.forename: Adriana
authors.initials: A
authors.lastname: Zabaleta
authors.forename: Grainne A
authors.initials: GA
authors.lastname: McMahon
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Lawrence
mesh_terms: D000818:Animals; D000838:Anions; D056649:Cathepsin G; D002403:Cathepsins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004705:Endocytosis; D042783:Endothelial Cells / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007249:Inflammation; D007700:Kinetics; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008168:Lung / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation; D009504:Neutrophils / Q000378:metabolism; D010179:Pancreas / Q000201:enzymology; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D012697:Serine Endopeptidases; D013997:Time Factors; D000514:alpha 1-Antichymotrypsin / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000378:metabolism
chemical_list: D000838:Anions; D004791:Enzyme Inhibitors; D017395:Plasminogen Activator Inhibitor 1; D000514:alpha 1-Antichymotrypsin; D000515:alpha 1-Antitrypsin; D002403:Cathepsins; D012697:Serine Endopeptidases; C534094:CTSG protein, human; D056649:Cathepsin G; C534096:Ctsg protein, mouse; D019272:Leukocyte Elastase